ADC Therapeutics to Engage with Investors at Upcoming Events
ADC Therapeutics SA (NYSE: ADCT), a pioneering leader in the advanced development of antibody-drug conjugates (ADCs), has exciting news regarding their participation in two prominent investor conferences this November. These engagements are part of the company's ongoing commitment to connecting with investors and sharing insights about their innovative therapies.
Upcoming Conferences
The first event is the Guggenheim Securities Healthcare Innovation Conference, set to be held on November 11, 2024. During this conference, Chief Executive Officer Ameet Mallik will present in a fireside chat format at 11:00 a.m. ET. This event promises to be a fantastic opportunity for investors to hear directly from the leadership of ADC Therapeutics about the company's future strategies and innovations.
Guggenheim Securities Healthcare Innovation Conference
The panel will give insights into ADC Therapeutics’ advancements and address queries from investors. Ameet Mallik's participation highlights the significance of this meeting, allowing stakeholders to engage meaningfully with the company’s vision.
Jefferies London Healthcare Conference
Following the Guggenheim event, ADC Therapeutics will also be featured at the Jefferies London Healthcare Conference on November 19, 2024. Ameet Mallik will again represent the company in a similar format, speaking at 11:00 a.m. GMT. This conference will delve deeper into ADC technology and its impact on patient care.
Global Reach and Strategic Advancements
These conferences provide a valuable platform for dialogue around ADC Therapeutics' ongoing clinical developments, particularly focusing on products like ZYNLONTA (loncastuximab tesirine-lpyl). This ADC received accelerated approval from the FDA for treating relapsed or refractory diffuse large B-cell lymphoma, marking a significant achievement.
Transforming Treatment Paradigms
ADC Therapeutics is committed to revolutionizing treatment options for patients with hematologic malignancies and solid tumors. Their focus on proprietary ADC technology exemplifies their dedication to enhance patient outcomes and broaden the therapeutic landscape.
About ADC Therapeutics
Founded as a commercial-stage company, ADC Therapeutics is advancing multiple ADCs through clinical and preclinical stages. The company's innovative approach is driving transformations in how specific cancers are treated, establishing themselves as leaders in the field.
For ongoing updates and information on their developments, interested parties can access the Events & Presentations page through the ADC Therapeutics' website. The company aims to provide comprehensive updates and a replay option for their conducted webcasts, ensuring that no interested investor misses out on crucial information.
This November, as ADC Therapeutics (NYSE: ADCT) showcases its enthusiasm and commitment at these conferences, stakeholders are encouraged to engage with the content. The focus on robust ADC technology as a transformative solution in oncology provides a compelling narrative for investors looking for groundbreaking advancements in drug development.
Frequently Asked Questions
What is ADC Therapeutics known for?
ADC Therapeutics is a leader in the development of antibody-drug conjugates, designed to target and treat various cancers.
When is ADC Therapeutics presenting at the conferences?
ADC Therapeutics will participate in the Guggenheim Securities Healthcare Innovation Conference on November 11, and in the Jefferies London Healthcare Conference on November 19.
Who is the CEO of ADC Therapeutics?
Ameet Mallik serves as the Chief Executive Officer of ADC Therapeutics and will be presenting at both conferences.
What is ZYNLONTA?
ZYNLONTA is an ADC developed by ADC Therapeutics that has received FDA approval for treating certain types of lymphoma.
How can I learn more about ADC Therapeutics’ events?
To get the latest information and access webcasts, visit the Events & Presentations section on the ADC Therapeutics website.
